Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928714 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL1929028 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL3086491 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL696467 | 0.80 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL8219110 | 0.80 | PDE4B (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2273359 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| Hydrochloric Acid SCHEMBL2515606 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| Hydrochloric Acid SCHEMBL16343926 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL618472 | 0.79 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL30229034 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | SMN1; SMN2 93/4885NPC1 455/4885RAB9A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.